Subject: Specialty Quantity Limit Idhifa 2240-H P2026

Drug

IDHIFA  (enasidenib)

Policy:

Program Description

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. The recommended dosing parameters for the treatment of all FDA-approved indications fall within the standard limits. Coverage of an additional quantity may be reviewed on a case-by-case basis upon request.

Covered Quantities

Medication	Standard Limit
Idhifa (enasidenib) 100 mg tablet	30 tablets per 30 days
Idhifa (enasidenib) 50 mg tablet	30 tablets per 30 days

FDA-recommended Dosing

Recommended starting dose

100 mg once daily.

Dose reductions may be needed for adverse reactions.

Dose reduction

50 mg orally once daily.

Place of Service:

Outpatient

The above policy is based on the following references:

1.      Idhifa [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; January 2025.

Copyright Aetna Inc. All rights reserved. Pharmacy Clinical Policy Bulletins are developed by Aetna to assist in administering plan benefits and constitute neither offers of coverage nor medical advice. This Clinical Policy Bulletin contains only a partial, general description of plan or program benefits and does not constitute a contract. Aetna does not provide health care services and, therefore, cannot guarantee any results or outcomes. Participating providers are independent contractors in private practice and are neither employees nor agents of Aetna or its affiliates. Treating providers are solely responsible for medical advice and treatment of members. This Clinical Policy Bulletin may be updated and therefore is subject to change.

June 14, 2026